Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

被引:49
|
作者
Gruber, A
Speth, C
Lukasser-Vogl, E
Zangerle, R
Borg-von Zepelin, M
Dierich, MP
Würzner, R
机构
[1] Univ Innsbruck, Ludwig Boltzman Inst AIDS Forsch, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Inst Dermatol & Venereol, A-6020 Innsbruck, Austria
[3] Univ Gottingen, Inst Hyg, D-3400 Gottingen, Germany
来源
IMMUNOPHARMACOLOGY | 1999年 / 41卷 / 03期
基金
奥地利科学基金会;
关键词
Candida albicans; Indinavir; HIV-1;
D O I
10.1016/S0162-3109(99)00035-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The putative virulence factor secreted aspartyl proteinase (SAP) of Candida albicans and the human immunodeficiency virus type 1 (HIV-1) protease both belong to the aspartyl proteinase family. The present study demonstrates that the HIV-1 protease inhibitor Indinavir is a weak but specific inhibitor of SAP. In addition, Indinavir reduces the amount of cell bound as well as released SAP antigen from C. albicans. Furthermore, viability and growth of C. albicans are markedly reduced by Indinavir, These findings indicate that HIV-1 protease inhibitors may possess antifungal activity and we speculate that in vivo SAP inhibition may add to the resolution of mucosal candidiasis in HIV-1 infected subjects. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 50 条
  • [21] Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants
    Martinez-Picado, J
    Savara, AV
    Shi, L
    Sutton, L
    D'Aquila, RT
    VIROLOGY, 2000, 275 (02) : 318 - 322
  • [22] Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
    Martinez-Picado, J
    Savara, LV
    Sutton, L
    D'Aquila, RT
    JOURNAL OF VIROLOGY, 1999, 73 (05) : 3744 - 3752
  • [23] Inhibition of cytokine-driven human immunodeficiency virus type 1 replication by protease inhibitor
    AlHarthi, L
    Roebuck, KA
    Kessler, H
    Landay, A
    JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (05): : 1175 - 1179
  • [24] Macrophage-Mediated Responses to Candida albicans in Mice Expressing the Human Immunodeficiency Virus Type 1 Transgene
    Goupil, Mathieu
    Trudelle, Emilie Belanger
    Dugas, Veronique
    Racicot-Bergeron, Catherine
    Aumont, Francine
    Senechal, Serge
    Hanna, Zaher
    Jolicoeur, Paul
    de Repentigny, Louis
    INFECTION AND IMMUNITY, 2009, 77 (09) : 4136 - 4149
  • [25] Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation
    Iga, M
    Matsuda, Z
    Okayama, A
    Sugiura, W
    Hashida, S
    Morishita, K
    Nagai, Y
    Tsubouchi, H
    JOURNAL OF VIROLOGICAL METHODS, 2002, 106 (01) : 25 - 37
  • [26] Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro
    Merrill, DP
    Manion, DJ
    Chou, TC
    Hirsch, MS
    JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (01): : 265 - 268
  • [27] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
    Acosta, EP
    Kakuda, TN
    Brundage, RC
    Anderson, PL
    Fletcher, CV
    CLINICAL INFECTIOUS DISEASES, 2000, 30 : S151 - S159
  • [28] Resistance to human immunodeficiency virus type 1 protease inhibitors
    Boden, D
    Markowitz, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2775 - 2783
  • [29] Human immunodeficiency virus type 1 group M protease in Cameroon: Genetic diversity and protease inhibitor mutational features
    Fonjungo, PN
    Mpoudi, EN
    Torimiro, JN
    Alemnji, GA
    Eno, LT
    Lyonga, EJ
    Nkengasong, JN
    Lal, RB
    Rayfield, M
    Kalish, ML
    Folks, TM
    Pieniazek, D
    JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (03) : 837 - 845
  • [30] Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments
    Wu, TD
    Schiffer, CA
    Gonzales, MJ
    Taylor, J
    Kantor, R
    Chou, SW
    Israelski, D
    Zolopa, AR
    Fessel, WJ
    Shafer, RW
    JOURNAL OF VIROLOGY, 2003, 77 (08) : 4836 - 4847